Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 17/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29622095 | 0.83 | HDAC4 (0.71) | HDAC4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7822328 | 0.82 | HDAC4 (0.69) | HDAC4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17147282 | 0.81 | HDAC4 (0.68) | HDAC4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27907597 | 0.80 | HDAC4 (0.67) | HDAC4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13485795 | 0.80 | HDAC4 (1.00) | HDAC4MEN1KMT2ANPSR1 | |
| SCHEMBL28173850 | 0.79 | HDAC4 (0.66) | HDAC4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8110741 | 0.79 | HDAC4 (0.65) | HDAC4MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17502816 | 0.78 | HDAC4 (1.00) | HDAC4MEN1KMT2ANPSR1 | |
| SCHEMBL16132896 | 0.78 | HDAC4 (1.00) | HDAC4MEN1KMT2ANPSR1 | |
| SCHEMBL16132818 | 0.78 | HDAC4 (0.63) | HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783488-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-10-10 | — | — | US | claimed |
| US-20160039745-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | BIOFOCUS DPI LIMITED (GB) | 2016-02-11 | — | — | US | claimed |
| US-9783488-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783488-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783488-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160039745-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | BIOFOCUS DPI LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160039745-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | BIOFOCUS DPI LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160039745-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | BIOFOCUS DPI LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| WO-2014159224-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039745-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885MEN1 3789/4885CYP1A2 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.